Deutsche Bank analyst Emmanuel Papadakis lowered the firm’s price target on Genmab (GMAB) to DKK 2,250 from DKK 2,400 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab announces 5.08% stake by Orbis Investment
- Genmab Discloses Orbis as 5.08% Major Shareholder
- Yaron Werber Reiterates Hold on Genmab, Citing Strong Execution but 2026‑Weighted Catalyst Risk Profile
- Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next
- Genmab Halts Early-Stage GEN1286 Cancer Trial: What Investors Should Know